Clinical Trials Logo

Acute Lung Injury clinical trials

View clinical trials related to Acute Lung Injury.

Filter by:

NCT ID: NCT02492204 Completed - Clinical trials for Acute Respiratory Distress Syndrome

The Role of IL33/ST2 Axis in ARDS Patients

Start date: July 2015
Phase:
Study type: Observational [Patient Registry]

The main objective is the study of the role of IL33/ST2 axis in the pathogenesis of ARDS, it´s value as prognosis marker and as therapeutic target.

NCT ID: NCT02490215 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Epidemiology of Acute Respiratory Distress Syndrome in Chinese ICUs

Start date: January 2015
Phase:
Study type: Observational

The acute respiratory distress syndrome(ARDS)has a high morbidity and mortality in patients admitted to intensive care units(ICUs). It represents a significant public health issue. No large nationwide, multicenters study of ARDS has been conducted in China. The purposes of this study are to analyse: 1)the incidence and outcomes of ARDS in ICU; 2) factors associated the mortality ; and 3) risk factors for development of ARDS .

NCT ID: NCT02475694 Completed - Inflammation Clinical Trials

Acute Lung Injury After Cardiac Surgery: Pathogenesis

ALI
Start date: September 2008
Phase: N/A
Study type: Observational

The purpose of the present study is to visualize the inflammatory response and coagulation disorders during cardiac surgery in order to identify possible predictors for acute lung injury postoperatively.

NCT ID: NCT02468908 Completed - Cystic Fibrosis Clinical Trials

Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects

Start date: May 2015
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single ascending (SAD), and multiple ascending dose (MAD) study conducted at a single clinical site within the UK. Healthy male and female subjects (on non-child bearing potential) will be enrolled to investigate single inhaled doses of molgramostim at 3 dose levels (Part 1) and multiple inhaled doses at 2 dose levels (Part 2). The 2 doses in the multiple ascending dose regimens will be administered once daily (QD) for 6 consecutive days. The clinical indication for inhaled molgramostim is the treatment of respiratory diseases such as aPAP, bronchiectasis and cystic fibrosis. The Clinical trial will involve 42 healthy participants. The trial is expected to last approximately 4 months.

NCT ID: NCT02468531 Recruiting - Acute Lung Injury Clinical Trials

Xenon Against Postoperative Oxygen Impairment

Start date: January 2015
Phase: N/A
Study type: Interventional

Acute lung injury (ALI) is the vital complication of Stanford type A aortic dissection. It is confirmed that Xenon has the significant protective effect on important organs and has no suppression on the cardiovascular system. Furthermore, our earlier trial has already clarified that static inflation with 50% Xenon during cardiopulmonary bypass could attenuate ALI for Standford A acute aortic dissection. However the protection effect was restricted for the limited time. Aimed to enhance the protection effect of Xenon, we designed this randomized trial that anesthesia with 50% xenon one hour before and after CPB and pulmonary static Inflation with 50%,75% and 100% Xenon during CPB respectively.

NCT ID: NCT02463773 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Diaphragm Ultrasound Vs Transpulmonary Pressure To Set PEEP in ARDS

Start date: June 2015
Phase: N/A
Study type: Interventional

This is a proof of concept study where the investigators aim to study the correlation between the use of a simple bedside ultrasound measurement of diaphragmatic muscle excursion with established (but time consuming) measurements made to optimize an important setting on the mechanical ventilator (positive end expiratory pressure or PEEP) in intubated adults with acute respiratory distress syndrome (ARDS) in the medical ICU.

NCT ID: NCT02457741 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Validation of a Simple Approach to Estimate Alveolar Recruitability in ARDS Patients

Start date: June 2015
Phase:
Study type: Observational

This study will test the validity of a new approach to assess alveolar recruitability at the bedside in comparison to direct measurements of lung volume and derecruitment.

NCT ID: NCT02450825 Completed - Pneumonia Clinical Trials

Comparison of Three Scores for Ultrasound Assessment and Monitoring of Pulmonary Aeration

Start date: July 2015
Phase: N/A
Study type: Interventional

This study is designed to compare three ultrasound-based aeration scores that were previously validated in specific populations, and to assess their correlation with computed tomographic measurement of pulmonary aeration in a population with different pathologies. Hypothesis: The "Loss of Aeration Score" will be more accurate than a simplified version and another widely used score, the "Lung Ultrasound Score".

NCT ID: NCT02444455 Recruiting - Clinical trials for Acute Respiratory Distress Syndrome

Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury

UCMSC-ALI
Start date: May 2015
Phase: Phase 1/Phase 2
Study type: Interventional

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with Acute Lung Injury ,open label, controlled prospective study.

NCT ID: NCT02439151 Completed - Clinical trials for Respiratory Distress Syndrome, Adult

New Lung Ventilation Strategies Guided by Transpulmonary Pressure in VV-ECMO for Severe ARDS

Start date: May 1, 2015
Phase: N/A
Study type: Interventional

Extracorporeal membrane oxygenation (ECMO) has been widely used in patients with severe acute respiratory distress syndrome (ARDS). But how to choose mechanical ventilation strategy is still not clear for severe ARDS patients supported by ECMO. Our previous work found that, compared to the traditional "lung rest" strategy, transpulmonary pressure guide new lung ventilation strategy can better maintain lung volume reduction lung collapse, atelectasis occurs. The severe ARDS patients receiving ECMO therapy were randomized divided into a new ventilation strategy group and the conventional ventilation strategy group. The new ventilation strategy is transpulmonary pressure guide ventilator setting method, and the conventional ventilation strategy is Extracorporeal Life Support Organization (ELSO) guide ventilation method. Compare the difference between the two groups of patients in lung injury, and explore the lung protection mechanism of new lung ventilation strategies guided by transpulmonary pressure. Our research group considered that transpulmonary pressure guide new lung ventilation strategy can provide more effective lung protection. And it will be further used in clinical work.